Syndax Pharmaceuticals stock kpis
Want to see SNDX full AI Analyst Report?
Revenue by Type
Syndax Pharmaceuticals reported revenue by type of $83.30M in Q3 2026, up 14.4% from Q2 2026 and up 81.6% year over year. This is the highest value since 2024.
Reveals how different revenue streams contribute to the overall income, highlighting the company’s diversification and potential reliance on specific products or services.
Revenue mix has shifted from lumpy milestone/license receipts to steadily growing commercial Product and Collaboration streams, reflecting rapid Revuforj adoption and partner-reported Niktimvo traction; this transition increases recurring revenue visibility but Syndax's reported collaboration receipts materially trail partner sales due to contract terms. Milestone income remains episodic, so near-term quarters can still swing. Management’s guidance of sustained commercial momentum and a strong cash runway supports execution, but high ongoing R&D/SG&A and variability in new patient starts are the main risks to profitability timing.
SNDX Revenue by Type
| Period | Product | Collaboration | Milestone & License | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $60.74M | $22.55M | $0.00 | $83.30M |
| Q2 2026Jun 30, 2026 | $54.70M | $18.09M | $0.00 | $72.79M |
| Q1 2026Mar 31, 2026 | $48.92M | $15.94M | $0.00 | $64.86M |
| Q4 2025Dec 31, 2025 | $44.20M | $19.39M | $5.14M | $68.73M |
| Q3 2025Sep 30, 2025 | $32.01M | $13.86M | $0.00 | $45.87M |
| Q2 2025Jun 30, 2025 | $28.60M | $9.36M | $0.00 | $37.96M |
| Q1 2025Mar 31, 2025 | $20.04M | $0.00 | $0.00 | $20.04M |
| Q4 2024Dec 31, 2024 | $7.68M | $0.00 | $0.00 | $7.68M |
| Q3 2024Sep 30, 2024 | $0.00 | $0.00 | $12.50M | $12.50M |
| Q2 2024Jun 30, 2024 | $0.00 | $0.00 | $3.50M | $3.50M |

